Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Intrinsic Value
Day One Biopharmaceuticals, Inc. operates as a holding company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DAWN.
Fundamental Analysis
Balance Sheet Decomposition
Day One Biopharmaceuticals Inc
| Current Assets | 375.3m |
| Cash & Short-Term Investments | 366.3m |
| Other Current Assets | 8.9m |
| Non-Current Assets | 774k |
| Long-Term Investments | 214k |
| PP&E | 560k |
| Current Liabilities | 29.5m |
| Accounts Payable | 2.6m |
| Accrued Liabilities | 25.9m |
| Other Current Liabilities | 1m |
Earnings Waterfall
Day One Biopharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-206.1m
USD
|
|
Operating Income
|
-206.1m
USD
|
|
Other Expenses
|
17.1m
USD
|
|
Net Income
|
-188.9m
USD
|
Free Cash Flow Analysis
Day One Biopharmaceuticals Inc
What is Free Cash Flow?
DAWN Profitability Score
Profitability Due Diligence
Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
DAWN Solvency Score
Solvency Due Diligence
Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DAWN Price Targets Summary
Day One Biopharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DAWN is 36.08 USD with a low forecast of 10.1 USD and a high forecast of 52.5 USD.
Ownership
DAWN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DAWN Price
Day One Biopharmaceuticals Inc
| Average Annual Return | -8.31% |
| Standard Deviation of Annual Returns | 34.25% |
| Max Drawdown | -80% |
| Market Capitalization | 1.4B USD |
| Shares Outstanding | 87 380 000 |
| Percentage of Shares Shorted | 12.83% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in South San Francisco, California and currently employs 42 full-time employees. The company went IPO on 2021-05-27. The company is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. The company seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. The company has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.
You don't have any saved screeners yet
